News & Updates

The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).

Ileus and pneumonia occur more frequently than previously reported among individuals with schizophrenia treated with clozapine, reveals a recent study, noting that such conditions also contribute to increased mortality.

First-line cemiplimab monotherapy continues to provide durable overall (OS) and progression-free survival (PFS) benefits at 5 years compared with chemotherapy in advanced nonsmall cell lung cancer (NSCLC) patients with PD-L1 expression ≥50 percent, according to the results of the EMPOWER-Lung 1 study presented at WCLC 2024.

Treatment with osimertinib following definitive chemoradiotherapy (CRT) demonstrates a manageable safety profile in patients with unresectable stage III EGFR-mutated nonsmall cell lung cancer (NSCLC), reports a study presented at WCLC 2024.

In the treatment of patients with pulmonary arterial hypertension, adding selexipag as a third medication sooner rather than later is crucial to help prevent hospitalization and disease progression, as suggested in an emulated target trial.

A prospective cohort study has shown that in patients aged <18 years hospitalized for acute SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C), neurologic manifestations during the infection are common and may predispose them more to new neurocognitive or functional morbidity at discharge.